Companies are eyeing a bill in Congress that could overhaul Medicare drug pricing
By Staff Writer|February 01, 2007 at 07:00 PM
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
The swift passage by the Democrat-led House of a bill requiring the federal government to negotiate Medicare drug prices sets the stage for what is certain to be a key issue in the 2008 elections. The bill calls upon the Health and Human Services (HHS) secretary to negotiate with drug companies on behalf of seniors, while at the same time barring the government from setting up a formulary as a means of negotiating. Those who favor the bill say it will mean lower drug prices, thus keeping beneficiaries from falling into the “doughnut hole” gap in coverage.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing. Once you are an ALM digital member, you’ll receive:
Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices,
case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
Exclusive discounts on ALM and Treasury & Risk events.
Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.